COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,891 Articles (22,568 medRxiv, 8,323 bioRxiv)

Most recent first Previous |  Page 603: Articles 6021-6030  | Next

Expression profiling of immune-response-genes common in SARS-CoV-1 and influenza A virus disease, viz-a-viz neutropenia disorder, using integrated bioinformatics tools
Olaniyi, A. C., Oluwadamilola, O. D., Oluwabunmi, A. T.
10.1101/2022.09.09.507303 — Posted: 2022-09-10
A new and highly effective method for predicting T-cell response targets implemented on SARS-CoV-2 data
Flegr, J., Zahradnik, D.
10.1101/2022.09.09.507307 — Posted: 2022-09-09
SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction
Narwal, M., Armache, J.-P., Edwards, T., Murakami, K. S.
10.1101/2022.09.09.507133 — Posted: 2022-09-09
A novel biopolymer for mucosal adjuvant against respiratory pathogens
Hoover, A. R., More, S., Liu, K., West, C. L., Valerio, T. I., Yu, N., Villalva, C., Kumar, A., Alleruzzo, L., Lam, S. S. K., Hode, T., Papin, J. F., Chen, W. R.
10.1101/2022.09.07.506979 — Posted: 2022-09-09
Cellular stress modulates severity of the acute respiratory distress syndrome in COVID-19
Rico-Llanos, G., Porras, O., Escalante, S., Vazquez, D., Valiente, L., Castillo, M., Perez-Tejeiro, J. M., Baglietto, D., Becerra, J., Reguera, J. M., Duran, I., Csukasi, F.
10.1101/2022.09.09.507257 — Posted: 2022-09-09
Use of the particle agglutination/particle agglutination-inhibition test for antigenic analysis of SARS-CoV-2
Kobayashi, J., Matsuyama, S., Shirakura, M., Arita, T., Suzuki, Y., Asanuma, H., Watanabe, S., Hasegawa, H., Nakamura, K.
10.1101/2022.09.08.507221 — Posted: 2022-09-09
Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern
ONeill, A., Kala, M. P., Tan, C. W., Saron, W. A. A., Mantri, C. K., Rathore, A. P. S., Wang, L.-F., St. John, A. L.
10.1101/2022.09.09.507250 — Posted: 2022-09-09
A cross-sectional study of low birth satisfaction among Iranian postpartum women during COVID-19 epidemics fifth wave
Mortazavi, F., Mehrabadi, M.
10.1101/2022.09.08.22279714 — Posted: 2022-09-09
Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., Siggins, M. K., Swieboda, D., Sidhu, J. K., Efstathiou, C., Moore, S. C., Davis, C., Mohamed, N., Nunag, J., King, C., Thompson, A. A. R., Rowland-Jones, S. L., Docherty, A. B., Chalmers, J. D., Ho, L.-p., Horsley, a., Raman, B., Poinasamy, K., Marks, M., Kon, O. M., Howard, L., Wootton, D. G., Dunachie, S., Quint, J. K., Evans, R. A., Wain, L. V., Fontanella, S., de Silva, T. I., Ho, A., Harrison, E. M., Baillie, J. K., Semple, M. G., Brightling, C., Thwaites, R., Turtle, L., Openshaw, P. J., ISARIC4C Investigators, , PHOSP-COVID collaborative group
10.1101/2022.09.09.22279759 — Posted: 2022-09-09
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Huang, Z., Xu, S., Liu, J., Wu, L., Qiu, J., Wang, N., Ren, J., Li, Z., Guo, X., Tao, F., Chen, J., Lu, D., Sun, X., Wang, W.
10.1101/2022.09.04.22279587 — Posted: 2022-09-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).